Current Approaches and Tools Used in Drug Development Against Parkinson's Disease

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2021 Jul 2

PMID 34208760

Citations 7

Authors

Oliwia Koszla

Piotr Stepnicki

Agata Zieba

Angelika Grudzinska

Dariusz Matosiuk

Agnieszka A Kaczor

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease is a progressive neurodegenerative disorder characterized by the death of nerve cells in the substantia nigra of the brain. The treatment options for this disease are very limited as currently the treatment is mainly symptomatic, and the available drugs are not able to completely stop the progression of the disease but only to slow it down. There is still a need to search for new compounds with the most optimal pharmacological profile that would stop the rapidly progressing disease. An increasing understanding of Parkinson's pathogenesis and the discovery of new molecular targets pave the way to develop new therapeutic agents. The use and selection of appropriate cell and animal models that better reflect pathogenic changes in the brain is a key aspect of the research. In addition, computer-assisted drug design methods are a promising approach to developing effective compounds with potential therapeutic effects. In light of the above, in this review, we present current approaches for developing new drugs for Parkinson's disease.

Citing Articles

Using computer modeling to find new LRRK2 inhibitors for parkinson's disease.

Garcia M, Cuesta S, Mora J, Paz J, Marrero-Ponce Y, Alexis F Sci Rep. 2025; 15(1):4085.

PMID: 39900949 PMC: 11790940. DOI: 10.1038/s41598-025-86926-8.

A Wonderful Journey: The Diverse Roles of Adenosine Deaminase Action on RNA 1 (ADAR1) in Central Nervous System Diseases.

Cheng L, Liu Z, Shen C, Xiong Y, Shin S, Hwang Y CNS Neurosci Ther. 2025; 31(1):e70208.

PMID: 39753993 PMC: 11702419. DOI: 10.1111/cns.70208.

The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain.

Martos D, Lorinczi B, Szatmari I, Vecsei L, Tanaka M Int J Mol Sci. 2024; 25(6).

PMID: 38542368 PMC: 10970565. DOI: 10.3390/ijms25063394.

Conformational dynamics of α-synuclein and study of its intramolecular forces in the presence of selected compounds.

Khatooni Z, Akhtari K, Wilson H Sci Rep. 2023; 13(1):19020.

PMID: 37923923 PMC: 10624887. DOI: 10.1038/s41598-023-46181-1.

Molecular and Structural Insight into Adenosine A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach.

Karati D, Mukherjee S, Roy S Mol Neurobiol. 2023; 60(10):5987-6000.

PMID: 37391647 DOI: 10.1007/s12035-023-03441-5.

References

Agis-Torres A, Solhuber M, Fernandez M, Sanchez-Montero J . Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease. Curr Neuropharmacol. 2014; 12(1):2-36. PMC: 3915347. DOI: 10.2174/1570159X113116660047. View

Edmondson R, Broglie J, Adcock A, Yang L . Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014; 12(4):207-18. PMC: 4026212. DOI: 10.1089/adt.2014.573. View

Van der Schyf C . The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol. 2011; 4(3):293-8. DOI: 10.1586/ecp.11.13. View

Morphy R, Kay C, Rankovic Z . From magic bullets to designed multiple ligands. Drug Discov Today. 2004; 9(15):641-51. DOI: 10.1016/S1359-6446(04)03163-0. View

Li W, Ma K, Jiang X, Yang R, Lu P, Nie B . Molecular mechanism of panaxydol on promoting axonal growth in PC12 cells. Neural Regen Res. 2018; 13(11):1927-1936. PMC: 6183029. DOI: 10.4103/1673-5374.239439. View

Boeckler F, Gmeiner P . Dopamine D3 receptor ligands: recent advances in the control of subtype selectivity and intrinsic activity. Biochim Biophys Acta. 2007; 1768(4):871-87. DOI: 10.1016/j.bbamem.2006.12.001. View

Zhang X, Yin M, Zhang M . Cell-based assays for Parkinson's disease using differentiated human LUHMES cells. Acta Pharmacol Sin. 2014; 35(7):945-56. PMC: 4088286. DOI: 10.1038/aps.2014.36. View

Rozpedek-Kaminska W, Siwecka N, Wawrzynkiewicz A, Wojtczak R, Pytel D, Diehl J . The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases. Int J Mol Sci. 2020; 21(6). PMC: 7139310. DOI: 10.3390/ijms21062108. View

Smits L, Schwamborn J . Midbrain Organoids: A New Tool to Investigate Parkinson's Disease. Front Cell Dev Biol. 2020; 8:359. PMC: 7248385. DOI: 10.3389/fcell.2020.00359. View

10.

Wang L, Cai X, Shi M, Xue L, Kuang S, Xu R . Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson's disease via the activation of Nrf2/keap1 pathway. Eur J Med Chem. 2020; 199:112385. DOI: 10.1016/j.ejmech.2020.112385. View

11.

Chavarria D, Fernandes C, Silva V, Silva C, Gil-Martins E, Soares P . Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies. Eur J Med Chem. 2019; 185:111770. DOI: 10.1016/j.ejmech.2019.111770. View

12.

Tang L, Huang C, Zhong J, He J, Guo J, Liu M . Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect. Eur J Med Chem. 2019; 168:221-231. DOI: 10.1016/j.ejmech.2019.02.026. View

13.

Xicoy H, Wieringa B, Martens G . The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener. 2017; 12(1):10. PMC: 5259880. DOI: 10.1186/s13024-017-0149-0. View

14.

Kovalevich J, Langford D . Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013; 1078:9-21. PMC: 5127451. DOI: 10.1007/978-1-62703-640-5_2. View

15.

Morphy R, Rankovic Z . Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005; 48(21):6523-43. DOI: 10.1021/jm058225d. View

16.

Alberio T, Mammucari C, DAgostino G, Rizzuto R, Fasano M . Altered dopamine homeostasis differentially affects mitochondrial voltage-dependent anion channels turnover. Biochim Biophys Acta. 2014; 1842(9):1816-22. DOI: 10.1016/j.bbadis.2014.06.033. View

17.

Hu X, Lin J, Lv X, Feng J, Zhang X, Wang H . Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo. Eur J Med Chem. 2018; 151:261-271. DOI: 10.1016/j.ejmech.2018.03.081. View

18.

Xu Q, Shenoy S, Li C . Mouse models for LRRK2 Parkinson's disease. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S186-9. DOI: 10.1016/S1353-8020(11)70058-X. View

19.

Curtius H, Wolfensberger M, Steinmann B, Redweik U, Siegfried J . Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr. 1974; 99(0):529-40. DOI: 10.1016/s0021-9673(00)90882-3. View

20.

Shao Y, Ma X, Paira P, Tan A, Herr D, Lim K . Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment. PLoS One. 2018; 13(1):e0188212. PMC: 5755735. DOI: 10.1371/journal.pone.0188212. View